世界の遺伝子治療市場展望：腫瘍/感染症/遺伝病/心臓血管疾患/糖尿病/神経疾患治療...市場調査レポートについてご紹介

1. Analyst View
2. Research Methodology
3. Gene Therapy – An Introduction
3.1 Classification of Gene Therapy Techniques
3.2 Physical Methods of Gene Transfer
3.2.1 Electroporation
3.2.2 Hydrodynamic
3.2.3 Microinjection
3.2.4 Particle Bombardment
3.2.5 Ultrasound-mediated Transfection
3.3 Vectors for Gene Therapy
3.3.1 Adenoviral Vectors
3.3.2 Adeno-associated Virus Vectors
3.3.3 Retroviral Vectors
3.3.4 Lentiviral Vectors
3.3.5 Plasmid DNA
4. Industry Trends and Drivers
4.1 Industry Trends
4.1.1 Gene Silencing: Gaining Momentum
4.1.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
4.1.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
4.1.4 Nanotechnology: Empowering Gene Therapy
4.1.5 Gene Therapy: A New Hope to Treat Blindness
4.1.6 Gene Therapy: Potential Cure for Cancer
4.2 Market Drivers
4.2.1 Failure of Conventional Therapies to Treat Cancers
4.2.2 Entry of Gene Therapies in Developed Nations
4.2.3 Rising Incidence of Chronic and Life Threatening Diseases
4.2.4 Growing Interest of Venture Capital Firms
5. Market Restraints
5.1 High Cost of Treatment
5.2 Stringent Regulatory Laws & Safety Concerns
5.3 Pitfalls in Current Technique
6. Gene Therapy Market Outlook
6.1 Market Size and Growth
6.2 Gene Therapy Clinical Trial Assessment
6.2.1 By Geography
6.2.2 By Indication
6.2.3 By Gene Type
6.2.4 By Vector
6.2.5 By Clinical Trial Phase
6.3 Gene Therapy Market by Application
6.3.1 Oncology
6.3.1.1 Key Approaches
6.3.1.2 Recent Advancements
6.3.2 Infectious Diseases
6.3.2.1 Key Approaches
6.3.2.2 Recent Advancements
6.3.3 Genetic Disorders
6.3.3.1 Key Approaches
6.3.3.2 Recent Advancements
6.3.4 Cardiovascular Disorders
6.3.4.1 Key Approaches
6.3.4.2 Recent Advancements
6.3.5 Diabetes Mellitus
6.3.5.1 Key Approaches
6.3.5.2 Recent Advancements
6.3.6 Neurological Disorders
6.3.6.1 Key Approaches
6.3.6.2 Recent Advancements
7. Gene Therapy Market – Regulatory Landscape
7.1 US
7.1.1 Regulatory Landscape
7.1.2 Recent Advancements
7.2 Europe
7.2.1 Regulatory Landscape
7.2.2 Recent Advancements
7.3 Australia
7.3.1 Regulatory Landscape
7.4 Canada
7.4.1 Regulatory Landscape
7.5 Japan
7.5.1 Regulatory Landscape
7.5.2 Recent Advancement
7.6 China
7.6.1 Regulatory Landscape
7.7 India
7.7.1 Regulatory Landscape
7.7.2 Recent Advancements
8. Advanced Gene Therapy Drugs
8.1 Collategene
8.2 Allovectin-7
8.3 Generx
8.4 Glybera
9. Mergers and Acquisitions
9.1 Sangamo BioSciences to Acquire Gene Therapy Company Ceregene.
9.2 Baxter to Acquire Chatham Therapeutics
9.3 Bluebird Bio Acquired Privately Held Gene-Editing Company
9.4 Miltenyi Acquired Gene Therapy Assets from Lentigen
9.5 Dutch Player UniQure to Acquire InoCard GmbH for CHF Therapy.
10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People)
10.1 Spark Therapeutics, LLC
10.2 ViroMed Co. Ltd. dba VM BioPharma
10.3 Advantagene Inc
10.4 Bluebird Bio
10.5 Sanofi
10.6 Genzyme – A Sanofi Company
10.7 Kolon Life Science
10.8 Vical Inc
10.9 Oxford BioMedica
10.10 Genethon

List of Figures:

Figure 6-1: Global – Gene Therapy Market (Million US$), 2013 & 2018
Figure 6-2: Number of Gene Therapy Clinical Trials Approved Worldwide (2004-2014)
Figure 6-3: Geographical Distribution of Gene Therapy Clinical Trials by Continents till June, 2014
Figure 6-4: Geographical Distribution of Gene Therapy Clinical Trials by Countries June, 2014
Figure 6-5: Gene Therapy Clinical Trials by Indication till June, 2014
Figure 6-6: Percentage of Gene Types Transferred in Gene Therapy Trials till June, 2014
Figure 6-7: Percentage of Vectors Used in Gene Therapy Trials till June, 2014
Figure 6-8: Percentage of Gene Therapy Trials by Phase till June, 2014
Figure 7-1: US – Number of New Cell Therapy and Gene Therapy Products Submission to FDA (2003-2010)
Figure 7-2: Japan – Evaluation System of Gene Therapy Clinical Trial
Figure 7-3: Number of Gene Therapy Labs in India

List of Tables:

Table 4-1: Gene Therapies under Development in the US
Table 4-2: Gene Therapies under Development in Europe
Table 4-3: Gene Therapy Companies Funded by Venture Capital Firms
Table 6-1: Human Gene Transfer Trials Approved by Condition till 2012
Table 6-2: Key Ongoing Gene Therapy Clinical Trials
Table 6-3: Prevalence of Key Single Gene Disorders
Table 6-4: Vectors Used for Cardiovascular Gene Transfer
Table 7-1: Number of Approved Gene Therapy Protocols
Table 7-2: China – Key Players and their Products in Gene Therapy
Table 8-1: Key Advanced Gene Therapy Drugs
Table 8-2: Unmet Need Analysis for Collategene
Table 8-3: Potential Market Size of Generx (Million US$)
Table 10-1: Spark Therapeutics LLC – Clinical Pipeline in Gene Therapy
Table 10-2: ViroMed Co.Ltd – Clinical Pipeline in Gene Therapy
Table 10-3: Advantagene Inc – Clinical Pipeline in Gene Therapy
Table 10-4: Bluebird Bio – Clinical Pipeline in Gene Therapy
Table 10-5: Sanofi – Clinical Pipeline in Gene Therapy
Table 10-6: Genzyme – Clinical Pipeline in Gene Therapy
Table 10-7: Kolon Life Science – Clinical Pipeline in Gene Therapy
Table 10-8: Vical – Clinical Pipeline in Gene Therapy
Table 10-9: Oxford Biomedica – Clinical Pipeline in Gene Therapy
Table 10-10: Genethon – Clinical Pipeline in Gene Therapy